BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 25,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the transaction, the executive vice president now owns 302,046 shares in the company, valued at $6,394,313.82. The trade was a 7.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

BioLife Solutions Stock Up 11.5 %

Shares of BLFS stock opened at $25.01 on Thursday. The firm has a market capitalization of $1.16 billion, a P/E ratio of -23.59 and a beta of 1.88. BioLife Solutions, Inc. has a 1 year low of $11.91 and a 1 year high of $28.88. The firm’s fifty day moving average price is $23.96 and its two-hundred day moving average price is $22.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors have recently added to or reduced their stakes in BLFS. Vanguard Group Inc. grew its position in shares of BioLife Solutions by 11.5% in the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock valued at $53,208,000 after acquiring an additional 296,727 shares during the period. Fred Alger Management LLC lifted its stake in BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares during the last quarter. State Street Corp lifted its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC grew its holdings in BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in BioLife Solutions by 9.1% in the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after buying an additional 66,422 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BLFS. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities boosted their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.